Insider Transactions in Q2 2021 at Natures Sunshine Products Inc (NATR)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 05
2021
|
Robert B Mercer Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+4.99%
|
-
|
|
May 05
2021
|
Mary Beth Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+7.03%
|
-
|
|
May 05
2021
|
Richard D Moss Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+15.15%
|
-
|
|
May 05
2021
|
Robert D Straus Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+12.06%
|
-
|
|
May 05
2021
|
Heidi Wissmiller Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+27.52%
|
-
|
|
May 05
2021
|
John Christopher Teets Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+8.45%
|
-
|
|
May 05
2021
|
Lily Zou Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+20.46%
|
-
|
|
May 03
2021
|
Joseph W Baty EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,413
-1.23%
|
$68,260
$20.6 P/Share
|
|
May 03
2021
|
Joseph W Baty EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,650
+3.0%
|
-
|
|
May 03
2021
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,025
-1.26%
|
$260,500
$20.6 P/Share
|
|
May 03
2021
|
Terrence Moorehead Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,092
+3.09%
|
-
|
|
Apr 12
2021
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
711
+1.75%
|
-
|
|
Apr 12
2021
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,002
-0.3%
|
$19,038
$19.64 P/Share
|
|
Apr 12
2021
|
Terrence Moorehead Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,628
+2.27%
|
-
|
|
Apr 12
2021
|
Robert B Mercer Director |
BUY
Grant, award, or other acquisition
|
Direct |
972
+1.66%
|
-
|
|
Apr 12
2021
|
Heidi Wissmiller Director |
BUY
Grant, award, or other acquisition
|
Direct |
258
+4.72%
|
-
|
|
Apr 12
2021
|
Richard D Moss Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,380
+4.6%
|
-
|
|
Apr 12
2021
|
Joseph W Baty EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-0.13%
|
$3,382
$19.64 P/Share
|
|
Apr 12
2021
|
Joseph W Baty EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,977
+1.47%
|
-
|
|
Apr 12
2021
|
Robert D Straus Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,360
+3.3%
|
-
|
|
Apr 12
2021
|
John Christopher Teets Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,515
+2.38%
|
-
|
|
Apr 12
2021
|
Lily Zou Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,131
+5.94%
|
-
|
|
Apr 12
2021
|
Mary Beth Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,169
+1.47%
|
-
|
|
Apr 06
2021
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,668
-1.13%
|
$73,360
$20.13 P/Share
|
|
Apr 06
2021
|
Terrence Moorehead Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,320
+2.79%
|
-
|
|
Apr 06
2021
|
Joseph W Baty EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,042
-0.79%
|
$20,840
$20.13 P/Share
|
|
Apr 06
2021
|
Joseph W Baty EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,260
+3.13%
|
-
|
|
Apr 01
2021
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,897
-3.63%
|
$226,043
$19.5 P/Share
|